Vitrobio Pharma

Vitrobio Pharma is a French pharmaceutical laboratory specializing in the research and development of polymeric medical devices. The company's focus lies in the treatment of chronic diseases such as allergies, ENT conditions, and dermatology by targeting multiple proteins simultaneously. Their patented technology, which involves the use of natural polymers like tannins or synthetic materials, shows a strong affinity for disease-specific proteins, offering effective multitarget treatment. Furthermore, they have been concentrating on the development of AyurEssentiel, a novel concept for slow-release long-acting filmogen essential oils. This patented innovation aims to prolong the action and increase the effectiveness of essential oils through the progressive release of active compounds. Each formulation contains filmogen glycerol and essential oils, creating a film that slowly disintegrates, allowing the gradual liberation of essential oils and limiting their evaporation. Vitrobio Pharma's innovative approach to pharmaceutical R&D and their focus on multitarget treatment solutions make them a notable player in the manufacturing and pharmaceutical industries. Their commitment to pioneering technologies in drug delivery and disease treatment positions them as a company to watch in the pharmaceutical landscape. With a founding year of 1994, Vitrobio Pharma continues to demonstrate their dedication to advancing medical solutions for chronic diseases. This company presents an exciting opportunity for venture capital firms seeking to invest in cutting-edge pharmaceutical research and development companies in France.